© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
HER2-Positive Breast Cancer
Targeted Therapy in Early-Stage HER2+ Breast Cancer
July 31, 2020
Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.
Clinical Trials Remain Underway for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
July 30, 2020
Ian E. Krop, MD, PhD, discusses the importance of clinical trials further exploring the role of trastuzumab deruxtecan following the FDA’s approval of the agent as treatment of patients with HER2-positive metastatic breast cancer.
FDA Approves Trastuzumab Companion Diagnostic for Detection of HER2 in Breast Cancer
July 30, 2020
The FDA has approved the Ventana HER2 Dual ISH DNA Probe Cocktail assay as a companion diagnostic for trastuzumab and for the detection of the HER2 biomarker in patients with breast cancer.
Neratinib Plus Chemotherapy Improved PFS in HER2+ Breast Cancer With CNS Involvement
July 22, 2020
Neratinib plus capecitabine improved progression-free survival and time to intervention for central nervous system disease in patients with previously treated HER2-positive metastatic breast cancer compared with lapatinib plus capecitabine, results from the phase 3 NALA trial show.
The Evolving Role of Tucatinib in HER2-Positive Metastatic Breast Cancer
July 15, 2020
A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.
T-DM1 Shows Activity in HER2+ Metastatic Breast Cancer and Brain Metastases
July 11, 2020
An exploratory analysis of trastuzumab emtansine demonstrated activity and tolerability in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases participating in the prospective KAMILLA trial.
Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer
July 07, 2020
Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.
HER2CLIMB Study Shows Efficacy in HER2 Breast Cancer With Brain Metastases
July 01, 2020
Nancy U. Lin, MD, discusses the latest findings from the HER2CLIMB study of either tucatinib or placebo, added to trastuzumab and capecitabine, for patients with previously treated HER2-positive metastatic breast cancer who have brain metastases.
FDA Approves Subcutaneous Phesgo Regimen in HER2+ Early Breast Cancer
June 29, 2020
"The FDA approval of Phesgo reflects our commitment to improving outcomes for the many people living with HER2-positive breast cancer."
Genotypes and Comorbidities Associated with Trastuzumab-Induced Cardiotoxicity in HER2+ Breast Cancer
June 26, 2020
In a single-institution study, investigators found a correlation between certain genotypes and comorbidities and trastuzumab-induced cardiotoxicity among patients with HER2-positive breast cancer.